Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 5/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895033 | 0.92 | DDR1 (0.41) | DDR1DYRK1APTGS2PTGS1ALDH1A1 | |
| SCHEMBL10281054 | 0.87 | DDR1 (0.39) | DDR1ALDH1A1LMNAHPGDHTT | |
| SCHEMBL10280993 | 0.85 | ILK (0.38) | DDR1S1PR1 | |
| SCHEMBL16803714 | 0.84 | DYRK1A (0.39) | DYRK1AALDH1A1LMNAHPGDHTT | |
| SCHEMBL16779870 | 0.82 | S1PR1 (0.33) | DDR1PTGS2PTGS1ALDH1A1LMNA | |
| SCHEMBL14684598 | 0.81 | GAA (0.35) | DDR1ALDH1A1LMNAS1PR1 | |
| SCHEMBL29431591 | 0.81 | GAA (0.35) | DDR1ALDH1A1LMNAS1PR1 | |
| SCHEMBL15870389 | 0.81 | NPC1 (0.39) | DDR1PTGS2PTGS1ALDH1A1LMNA | |
| SCHEMBL16612971 | 0.80 | SLC22A12 (0.33) | DYRK1ASLC22A12S1PR1 | |
| SCHEMBL11895090 | 0.78 | NPSR1 (0.37) | HPGDS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2857397-B1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-9364000-B2 | Method of controlling pests with fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9364000-B2 | Method of controlling pests with fused heterocyclic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20150373982-A1 | METHOD OF CONTROLLING PESTS WITH FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150373982-A1 | METHOD OF CONTROLLING PESTS WITH FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-31 | — | — | US | disclosed |
| US-20150166573-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166573-A1 | FUSED HETEROCYCLIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2857397-A1 | FUSED HETEROCYCLIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2857397-A1 | FUSED HETEROCYCLIC COMPOUND | Sumitomo Chemical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150373982-A1 | METHOD OF CONTROLLING PESTS WITH FUSED HETEROCYCLIC COMPOUND | NR4A1, NR2E1, NR0B1 | DDR1 3233/4885DYRK1A 4785/4885PTGS2 1853/4885 |
| US-20150166573-A1 | FUSED HETEROCYCLIC COMPOUND | NR4A1, NR2E1, NR0B2 | DDR1 3287/4885DYRK1A 4817/4885PTGS2 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.